Navigation Links
Global Antibacterial Drugs Market to 2022: Antibacterial Drug Market will Hit $35.6 Billion by 2022, as Efforts Increase to Tackle Antimicrobial Resistance - Research and Markets
Date:2/16/2017

DUBLIN, Feb 16, 2017 /PRNewswire/ --

Research and Markets has announced the addition of the "Global Antibacterial Drugs Market to 2022 - Vaccines Retain Market Prominence While Pipeline Offers Innovative Approaches to Tackling Antimicrobial Resistance" report to their offering.

The antibacterial drug market is forecast to rise from around $27.1 billion in 2015 to $35.6 billion in 2022

The antibacterial drug market covers the drugs used in the prophylaxis and treatment of bacterial infections. With a growing global concern over antimicrobial resistance and its progressive growth, there is a pronounced need for innovation within this market. This report considers the key developments in this market, with particular focus on drugs indicated for use in pneumonia, methicillin-resistant staphylococcus aureus (MRSA), sepsis and tuberculosis.

The antibacterial market is currently dominated by vaccines, in particular those for the prevention of pneumococcal infections, diphtheria, tetanus and pertussis. However, recent years have seen key additions in the form of therapies for antibiotic-resistant bacteria, including strains with multi-drug resistance. The number of such products is expected to increase drastically between 2016 and 2022.

Scope

Antibiotic resistance has caused a surge in the development of antibiotics:

- How big is the antibiotic pipeline?

- How are companies attempting to overcome antibiotic resistance?

The antibacterial drug market is forecast to rise from around $27.1 billion in 2015 to $35.6 billion in 2022:

- How much will the approval of new products and the patent expiries of existing ones contribute to this market growth?

- Will vaccines continue to drive market revenue?

The pipeline contains a range of molecular targets:

- Which molecular targets are most popular in the current pipeline?

- How many late-stage products are active against drug-resistant bacteria?

- What are the commercial prospects for the most promising late-stage pipeline products?

Big Pharma maintains a strong presence within the antibacterial drug market:

- Which of the leading companies are expected to have the highest share of the market by 2022?

- Which of the leading pharmaceutical companies are expected to bring new products to market during the forecast period?

- Which companies rely heavily of revenues derived from antibacterial drugs?

Key Topics Covered:

1 Table of Contents

2 Introduction

3 Key Marketed Products

3.1 Overview

3.2 Cubicin (daptomycin) - Merck & Co

3.3 Augmentin - GlaxoSmithKline

3.4 Prevnar 13 - Pfizer

3.5 Infanrix - GlaxoSmithKline

3.6 Boostrix - GlaxoSmithKline

3.7 Zerbaxa - Merck and Co

3.8 Bexsero - GlaxoSmithKline

3.9 Zyvox - Pfizer

3.10 Conclusion

4 Pipeline Landscape Assessment

4.1 Overview

4.2 Pipeline Development Landscape

4.3 Mechanisms of Action in Pipeline

4.4 Clinical Trial Landscape

4.5 Conclusion

4.6 Assessment of Key Pipeline Products

4.6.1 Solithera - Cempra

4.6.2 Arikace - Insmed

4.6.3 Cadazolid - Actelion

4.6.4 Plazomicin (plazomicin sulfate) - Achaogen

4.6.5 V114 - Merck & Co.

4.6.6 Suvratoxumab (MEDI4893) - MedImmune

4.6.7 Pf-06290510 (SA4Ag vaccine) - Pfizer

4.6.8 PF-06425090 - Pfizer

4.6.9 Conclusion

5 Multi-Scenario Market Forecast to 2022

5.1 Overall Market Size

5.2 Generic Penetration

5.3 Revenue Forecast by Mechanism of Action

6 Company Analysis and Positioning

6.1 Revenue and Market Share Analysis by Company

6.1.1 Pfizer - Will it Maintain its Position as Market Leader?

6.1.2 GlaxoSmithKline - Will Revenues for Key Products Continue to Grow Over Forecast Period?

6.1.3 Merck & Co - How Will Key Approvals and Patent Expiries Affect Revenue?

6.1.4 Allergan - Revenues to Rise Rapidly Following Market Entry

6.1.5 Cempra - Set to Enter the Market in 2017

6.1.6 Insmed - Set to Enter the Market in 2018

6.1.7 Otsuka - How Will the Approval of Deltyba Affect Otsuka's Market Share?

6.1.8 Roche - Revenues to Continue to Decline Due to Lack of Pipeline Products

6.1.9 Bayer - Steady Decline as All Products Off-Patent

6.1.10 AstraZeneca - Set to Revitalize its Position within the Market

6.2 Company Landscape

6.3 Marketed and Pipeline Portfolio Analysis

7 Strategic Consolidations

7.1 Licensing Deals

7.2 Co-development Deals

8 Appendix

For more information about this report visit http://www.researchandmarkets.com/research/5x7jmj/global

Media Contact:

Research and Markets

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470

For U.S./CAN Toll Free Call +1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907

Fax (outside U.S.): +353-1-481-1716

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/global-antibacterial-drugs-market-to-2022-antibacterial-drug-market-will-hit-356-billion-by-2022-as-efforts-increase-to-tackle-antimicrobial-resistance---research-and-markets-300408724.html


'/>"/>
SOURCE Research and Markets
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. Global Information Online Market Research Portal Provides Complimentary Sample Service for Customers to Preview Reports by Global Industry Analysts
2. Cumberland Pharmaceuticals To Present At The UBS Global Healthcare Conference In New York
3. The Rockley Group and Content Rules Ink Deal to Extend Global Reach
4. AcelRx Pharmaceuticals to Present at the UBS Global Healthcare Conference
5. Amgen To Present At The UBS Global Life Sciences Conference
6. HeartWare Presentation At The 2013 UBS Global Healthcare Conference To Be Webcast
7. Nektar Therapeutics President and CEO, Howard W. Robin, To Present at the 2013 UBS Global Healthcare Conference in New York City
8. PENTAX Medical And Hitachi-Aloka Medical Continue Joint Innovation And Global Leadership In Endoscopic Ultrasound Systems
9. Orexigen Therapeutics to Present at the UBS Global Healthcare Conference
10. TRACE Releases 2012 Global Enforcement Report
11. Valeant Pharmaceuticals To Present At 34th Annual Goldman Sachs Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2020)... (PRWEB) , ... July 01, 2020 , ... ... first time ever, Stratodesk NoTouch OS is available on NComputing devices. Thanks to ... both NComputing and Stratodesk have formed a new partnership that will make the ...
(Date:6/25/2020)... , ... June 25, 2020 , ... R3 Medical Training ... taking place in August at several locations. The first course is August 6-7, 2020 ... the course is being offered as a Virtual Live Stream option. , The two ...
(Date:6/25/2020)... ... 25, 2020 , ... The Heritage Downtown Active Senior Living Apartment Homes in ... over 100,000 positive cases of the coronavirus in the United States to date, their ... Heritage Downtown, their family members, as well as the Walnut Creek community. , ...
Breaking Medicine Technology:
(Date:6/28/2020)... Calif. (PRWEB) , ... June 26, 2020 , ... ... tougher. Inland Detox, the Inland Empire’s premier residential addiction treatment center, proudly announces ... services that now includes special preparation for recovery in a world affected by ...
(Date:6/28/2020)... MILWAUKEE (PRWEB) , ... June 28, 2020 , ... ... allergy/immunology societies around the world, dedicates World Allergy Week, from June 28 to ... pandemic caused by SARS CoV-2. , COVID-19, short for “coronavirus disease 2019”, is ...
(Date:6/24/2020)... ... ... At Allerio we have chosen to do things differently. At Allerio we solved ... to be portable, it had to be reliable, it had to be secure, it ... proud to announce that Allerio has passed all FCC and carrier certification requirements to ...
(Date:6/24/2020)... (PRWEB) , ... June 24, 2020 , ... Skyroam ... today a partnership with LabWare , the leading provider of enterprise software for ... WiFi connectivity as part of LabWare’s new Portable Disease Surveillance Lab (PDSL) kit. , ...
(Date:6/23/2020)... ... 2020 , ... Rritual , the premium brand in the emerging functional ... the President of North America’s leading mushroom adaptogens company. , Dr. Hart has ... his own family medicine clinic in London, Ontario, Canada where he regularly integrates plant-based ...
Breaking Medicine News(10 mins):